Mineralys Therapeutics Inc
MLYS
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.77B
Close$
$2.56
90.8% downside
Current Fair Value
90.8% downsideOvervalued by 90.8% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.77 Billion |
|---|---|
| Enterprise Value | $1.66 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-2.29 |
| Beta | 0.57 |
| Outstanding Shares | 82,834,752 |
Return
| Return on Equity | -23.78% |
|---|---|
| Return on Assets | -23.25% |
| Return on Invested Capital | -26.22% |
Valuation & Multiples
| P/E Ratio | -13.01 |
|---|---|
| PEG | 191.28 |
| Price to Sales | - |
| Price to Book Ratio | 3.96 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -9.9 |
| Enterprise Value to Net Income | -11 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 18, 2026
EPS Estimate
$-0.48
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
August 11, 2026
EPS Estimate
$-0.57
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 1.0490▼ 85.07% |
|---|---|
| Total Calls | 3,582,200▲ 21.99% |
| Total Puts | 3,757,900▼ 32.64% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 133.51%▲ 8.30% |
|---|---|
| Total Invested | $2.46B▼ 23.46% |
| Investors Holding | 229▼ 10.00% |
ESG Score
No data